glp-1 agonist weight loss medications alternatives List of approved and pending Excellent head-to-head comparison of current

In the SURMOUNT-2 study, which involved 938 adults with obesity or overweight and T2D, tirzepatide showed significant weight loss effects of 13.4% and 15.7% for the 10 and 15 mg doses, respectively, with over 80% of participants experiencing at least a 5% weight loss [92]

This distinction matters enormously for Medicare coverage, as you'll see below

Maximizing Health on GLP-1 Medications: The Role of Weight Training, Protein, and Creatine May 7, 2025 3 min read Medications like semaglutide (Ozempic) and tirzepatide (Mounjaro), part of the GLP-1 receptor agonist class, have revolutionized weight management and diabetes care

This risk was reduced even further in cases of prolonged treatment extending beyond three years (HR: 0.71), though GLP-1RA treatment for zero to one years (HR: 0.89) and one to three years (HR: 0.85) were not significant

Real-world analyses show that half of patients discontinue within a year